The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1373
ISSUE1373
September 19, 2011
Peginterferon Alfa-2b (Sylatron) for Melanoma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Peginterferon Alfa-2b (Sylatron) for Melanoma
September 19, 2011 (Issue: 1373)
The FDA has approved peginterferon alfa-2b (Sylatron – Merck) for adjuvant treatment of node-positive melanoma after surgical resection. Pegylated interferon has a longer duration of action than interferon alfa-2b (Intron A), which is also...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.